Overview

A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720

Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The study will assess the patients' satisfaction of treatment after 12 months treatment with fingolimod It also will assess the tolerability profile of fingolimod in a small population.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Fingolimod Hydrochloride